Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Oropharyngeal Neoplasms 3Nasopharyngeal Carcinoma 2Carcinoma 2Renal Pelvis and Ureter Urothelial Carcinoma 1Osteosarcoma 1NSCLC 1Mouth Neoplasms 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Gallbladder Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Squamous Cell 1

Interventions

Pemetrexed 2Gefitinib 2spartalizumab 1aflutinib 1Tyrosine Kinase Inhibitors 1Thalidomide 1Radiosurgery 1Platinum 1Immune Checkpoint Inhibitors 1Drug Therapy 1Axitinib 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × NSCLC × Platinum × Clear all
NCT01769066 2016-02-23

Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC

Fudan University

Phase 2/3 Completed
117 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡